TIMP3 and acute myeloid leukemia: In AML patients, aberrant TIMP3 methylation was significantly associated with an adverse cytogenetic prognosis, whilst methylated TIMP3 was less prevalent in patients with a favorable or intermediate cytogenetic risk.